Pulmonology
Emphysema
Alveolar walls destroyed, recoil lost — and air can no longer escape
Emphysema is the permanent enlargement of distal airspaces with destruction of alveolar walls. Lost elastic recoil and lost airway tethering cause dynamic airway collapse, air trapping, and the barrel chest. Smoking and α1-antitrypsin deficiency are the major causes.
- DefinitionPermanent alveolar enlargement + wall destruction
- Primary mechanismProtease-antiprotease imbalance
- Centrilobular patternUpper-lobe — smokers
- Panlobular patternLower-lobe — α1-AT deficiency
- α1-AT deficiency share1-3% of COPD cases
- Distinguishing PFTReduced DLCO (vs preserved in bronchitis)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
The destruction sequence
The healthy alveolus is a thin-walled sac about 200 μm across, sharing its wall with neighbors and embedded in a meshwork of pulmonary capillaries. The wall — elastin fibers wrapped around collagen — is what makes the lung springy: stretched during inspiration, it recoils during expiration like a deflating balloon. In emphysema, inflammatory cells release proteases that digest both elastin and collagen faster than the lung can repair them. Over years, septa thin, perforate, and finally rupture. Two small alveoli become one larger sac; many small sacs become one large bulla; the lung's microstructure is permanently rearranged into fewer, larger, less efficient air spaces.
The functional cost is double. First, the total surface area for gas exchange falls — from roughly 70 m² in a healthy adult to as little as 25-30 m² in severe disease. This appears on testing as a reduced DLCO. Second, and more important for the patient's breathing, the elastin scaffolding that held small airways open is gone. During inspiration the airways still open because the chest wall pulls outward; during expiration, when pleural pressure becomes positive, the unsupported airways collapse before the air behind them has fully escaped.
Dynamic airway collapse and air trapping
Small airways <2 mm in diameter have no cartilage; they depend entirely on the surrounding alveolar attachments to stay open. In healthy lung these attachments work like the guy wires of a tent — outward radial traction keeps the airway lumen patent at every lung volume. In emphysematous lung the attachments are destroyed. The airway becomes floppy. During forced exhalation, intrathoracic pressure rises and presses inward on the airway from outside; with no outward counter-traction, the airway closes. The "equal-pressure point" — where airway and pleural pressures are equal — migrates upstream into smaller airways with each successive breath, trapping air distally and raising end-expiratory volume.
This is why emphysema patients exhale slowly and through pursed lips: pursing creates a back-pressure that keeps the upstream airways open longer, allowing more air to escape before they collapse. Mechanically, the same logic underlies the use of PEEP (positive end-expiratory pressure) in mechanical ventilation, and the pop-off valves on bag-valve-mask devices.
Worked clinical example
A 52-year-old never-smoker man presents with two years of progressive dyspnea on exertion, no cough, normal sputum. Brother died at 58 of "lung disease." On exam: thin, tall, AP chest diameter increased, prolonged expiratory phase, distant breath sounds, no clubbing. SpO₂ 93% on room air, BMI 19.
Spirometry: FEV1 1.8 L (52% predicted), FVC 4.4 L (88% predicted), FEV1/FVC 0.41 — severe obstruction with relatively preserved FVC, classic for emphysema. DLCO 38% predicted — markedly reduced. Chest CT: panlobular emphysema, lower-lobe predominant, bullous changes in lower lobes. Given young age, never-smoking history, and lower-lobe pattern: α1-antitrypsin level checked — 21 mg/dL (low; normal >100). Genotype: PiZZ. Liver function tests mildly abnormal.
Management: AAT augmentation therapy (IV pooled AAT 60 mg/kg weekly), LABA + LAMA combination, hepatology referral, vaccination, pulmonary rehab, screening of family members for AAT deficiency. The two children both screen as PiMZ heterozygotes — they will not develop emphysema themselves at normal rates but should avoid smoking strictly. The brother had died undiagnosed; his unrecognized deficiency was the family proband event.
Centrilobular vs panlobular emphysema
| Feature | Centrilobular (centriacinar) | Panlobular (panacinar) |
|---|---|---|
| Anatomy destroyed | Respiratory bronchioles; central acinus | Entire acinus uniformly |
| Lobar predominance | Upper lobes | Lower lobes |
| Cause | Smoking | α1-antitrypsin deficiency (PiZZ) |
| Typical age at onset | 50-70 years | 30-50 years (younger if smoker) |
| Smoking required | Yes (or major equivalent exposure) | No — develops in non-smokers |
| Liver disease | No | Yes (Z-protein hepatic retention) |
| Targeted therapy | Smoking cessation; bronchodilators | AAT augmentation (weekly IV) |
| CT appearance | Punched-out lucencies, upper-lobe | Diffuse, uniform, lower-lobe |
Why emphysema matters
- Quality of life. Emphysema produces some of the worst chronic dyspnea in medicine — comparable to advanced heart failure in symptom burden.
- Spontaneous pneumothorax. Paraseptal emphysema is the cause in young thin men; bullous emphysema in older patients raises the risk.
- Lung transplant referral. Emphysema (including AAT deficiency) is the leading indication for lung transplantation in many centers.
- α1-AT screening. Underdiagnosed; every COPD patient under 45 and every patient with lower-lobe predominance should be tested.
- Lung volume reduction. Endobronchial one-way valves are now an effective, less invasive alternative to surgical LVRS in selected upper-lobe disease.
- Smoking-related cancer. Emphysema patients have a substantially elevated risk of lung cancer independent of smoking exposure — annual screening LDCT is warranted in eligible patients.
- Anesthesia. Hyperinflation, bullae, and dynamic collapse all complicate perioperative ventilation; specific protocols (longer expiratory time, low PEEP) apply.
Common misconceptions
- "Emphysema and COPD are the same thing." Emphysema is the alveolar destruction component; COPD also includes chronic bronchitis (airway disease) and is defined by airflow limitation, not by pathology.
- "You can hear emphysema as wheezing." Emphysema produces distant, diminished breath sounds; wheezing is more characteristic of bronchitic or asthmatic components.
- "Lost alveoli regrow with exercise." They do not — pulmonary rehab improves function via muscle conditioning and breathing technique, not regeneration.
- "AAT deficiency only matters if you smoke." PiZZ patients develop emphysema even as never-smokers — by their 50s on average — and benefit from augmentation regardless.
- "Bullae always need surgery." Only giant bullae compressing functional lung benefit from bullectomy; small bullae are observed.
- "DLCO is reduced in all COPD." DLCO is preserved in pure chronic bronchitis; its reduction specifically supports emphysematous involvement.
Frequently asked questions
What exactly is destroyed in emphysema?
The walls between adjacent alveoli — the alveolar septa — and the surrounding pulmonary capillaries embedded in them. These walls contain elastin fibers that provide the lung its springy recoil and collagen fibers that resist overdistension. Both are digested by inflammatory proteases — neutrophil elastase, MMP-9, MMP-12, cathepsin G — secreted by recruited neutrophils, macrophages, and CD8+ lymphocytes in response to inhaled toxins. The result is structural: many small alveoli (~150-300 μm) merge into fewer larger air sacs (sometimes >1 cm — bullae), with reduced total surface area for gas exchange. The diffusion capacity for carbon monoxide (DLCO) falls in proportion to the destruction.
Why does lost elastic recoil cause air trapping?
Healthy lung deflates passively because the elastin fibers stretched during inspiration recoil during expiration, driving air out. In emphysema the elastin is destroyed, so the lung's natural recoil pressure falls. Without surrounding alveolar tethering, small airways have no scaffolding to keep them open during expiration — they collapse under the intrathoracic pressure generated by exhalation, like a wet paper straw. The equal-pressure point (where airway pressure equals pleural pressure) moves upstream into smaller airways with each progressive breath, creating dynamic airway collapse. The patient must therefore exhale through pursed lips, generating positive expiratory pressure to keep airways open and reduce dead-space air trapping.
What is the protease-antiprotease hypothesis?
The lung is in constant protein turnover — proteases digest, antiproteases protect. The dominant inhibitor of neutrophil elastase is α1-antitrypsin (AAT), produced by the liver. In healthy lungs the balance favors preservation. In emphysema two forces tip it toward destruction: (1) inhaled smoke recruits inflammatory cells that release more protease and (2) oxidants in smoke chemically inactivate the methionine residue in AAT, lowering its inhibitory capacity. Hereditary AAT deficiency starts the patient on the wrong side of the balance from birth. The net effect is years of slow elastin and collagen digestion that the lung cannot adequately repair.
How does centrilobular emphysema differ from panlobular?
Centrilobular (centriacinar) emphysema affects the respiratory bronchioles in the center of the secondary pulmonary lobule, with relative sparing of the distal alveoli. It is upper-lobe predominant on imaging and is the typical pattern in smokers. Panlobular emphysema destroys the entire acinus uniformly — from respiratory bronchioles through alveolar ducts and sacs. It is lower-lobe predominant and is the classic pattern in α1-antitrypsin deficiency. Distal acinar (paraseptal) emphysema affects the periphery and is associated with spontaneous pneumothorax in young thin men. Each pattern has subtly different physiology and imaging appearance, but they share the same underlying biology: alveolar wall destruction with lost recoil.
What signs and tests confirm emphysema?
Symptoms — exertional dyspnea, often without cough; thin habitus; pursed-lip breathing — are nonspecific. The barrel chest, increased AP diameter, hyper-resonant percussion, and distant breath sounds are bedside clues. Spirometry shows the COPD pattern: FEV1/FVC <0.70, often with reduced FVC from air trapping and increased residual volume (RV). DLCO is markedly reduced — distinguishes emphysema from chronic bronchitis, which preserves DLCO. CT chest is the definitive imaging study: areas of low attenuation (-950 HU threshold), bullae, and pattern recognition (upper-lobe centrilobular vs lower-lobe panlobular). Quantitative CT measures emphysema extent. AAT level and genotype testing should be done in all COPD patients <45 or with lower-lobe predominance.
Is there any way to reverse emphysema?
Lost alveolar tissue cannot regrow with current therapy — but progression can be slowed and symptoms reduced. Smoking cessation halts further protease-driven destruction and slows FEV1 decline back toward the natural aging rate. Bronchodilators (LAMA + LABA) relieve dyspnea by reducing airway tone and dynamic hyperinflation. AAT augmentation (weekly IV pooled AAT) raises serum levels in PiZZ patients and slows lung function decline in selected cases. Lung volume reduction — surgical or endoscopic one-way valve placement — improves symptoms in upper-lobe-predominant emphysema by reducing hyperinflation. Lung transplant is the only definitive treatment for end-stage disease; 5-year survival is ~55%. Pulmonary rehabilitation improves exercise tolerance and quality of life independently of any drug.
What is a bulla and when does it matter?
A bulla is an emphysematous air space larger than 1 cm. When bullae enlarge to occupy more than one-third of a hemithorax they cause compressive atelectasis of adjacent normal lung — 'giant bullous disease' or vanishing-lung syndrome. Surgical bullectomy can restore meaningful function in this minority of patients. Subpleural bullae rupture into the pleural space causing spontaneous pneumothorax — common in tall thin young men with paraseptal emphysema, and in advanced bullous disease in older patients. Suspected pneumothorax in emphysema is harder to detect (already diminished breath sounds, hyper-resonant baseline) — and a tension pneumothorax in a lung with poor reserve can be rapidly fatal.